FDA Plans to Discuss the Negative Trial of AstraZeneca’s Drug Iressa With the Oncologic Drugs Advisory Committee in March.
Also in this 8-page Issue: Safety Warnings Are Added to Labels for Epo and Avastin.
Cancer Accounts for 23% of U.S. Deaths, American Cancer Society Says.
NCI Sets its Targets for Grant Success Rate and R01 Payline for FY05.
NIH Panel Calls for Further Research On End-of-Life Issues.
NAS Committee Urges Greater Rewards For Interdisciplinary Research.
CAM Therapies Should Be Held to Conventional Standards and Congress Should Toughen Dietary Supplements Act, IOM Panel Says.
Funding Opportunities Listed.
Trending Stories
- As Trump’s second term nears, Republican support for NIH is at a low point
By stonewalling GOP in the House, Biden’s HHS officials eroded bipartisan support for biomedical research - Cedars-Sinai spearheads first national certification program for COE staff at cancer centers
- Menin inhibitors emerge as new treatment for advanced AML
- Trump 2016: A look back at the 45th president’s impact on oncology
- Patient navigation benefits health systems, improves care
Initial data presented at the White House come a year after CMS payment began - Larry Einhorn reflects on his pioneering work on platinum-based chemotherapy at the AACI/CCAF annual meeting
